FidoCure®

About

FidoCure® is a biotechnology company dedicated to improving cancer care for dogs through precision medicine and AI-driven innovations. Founded by passionate dog lovers and scientists, the company aims to make advanced cancer treatments accessible to veterinary patients by utilizing advancements from human oncology. FidoCure® offers personalized cancer treatment plans that combine advanced diagnostics with targeted therapies. Their services include next-generation DNA sequencing to identify genetic mutations in canine tumors and AI-driven precision medicine that recommends tailored treatments. The company collaborates with veterinarians to implement innovative oncology protocols. Their flagship product, the FidoCure® Next Generation DNA Sequencing Test, uses human-grade sequencing technologies adapted for canine cancer, enabling mutation-specific therapies. They also provide targeted therapies that utilize FDA-approved human cancer drugs, repurposed for canine safety and efficacy. FidoCure® serves dog owners and veterinarians seeking advanced oncology solutions, emphasizing access to therapies that have traditionally been available only in human medicine. The company is backed by notable biotech investors, showcasing its commitment to merging veterinary science with cutting-edge technology.